Tech Company Financing Transactions
C4 Therapeutics Funding Round
C4 Therapeutics, operating out of Watertown, scored $73 million in funding from Cobro Ventures, Cormorant Asset Management and The Kraft Group.
Transaction Overview
Company Name
Announced On
1/8/2016
Transaction Type
Venture Equity
Amount
$73,000,000
Round
Series A
Investors
Proceeds Purpose
The Company is developing novel treatments in the field of targeted protein degradation using proprietary Degronimid technology.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
490 Arsenal Way 200
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Not Recorded
Overview
C4 Therapeutics (Nasdaq: CCCC) is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Marc Cohen
Chief Financial Officer
William McKee
Chief Medical Officer
Adam Crystal
Chief Scientific Officer
Stew Fisher
Browse more venture capital transactions:
Prev: 1/8/2016: Razzor venture capital transaction
Next: 1/8/2016: Bottlenose venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs